MaxCyte is a global cell-based medicines and life sciences company applying its proprietary cell engineering technology platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance development of innovative medicines, particularly in cell therapy, including the use of gene editing tools in treatment of genetic diseases and immuno-oncology approaches to cancer treatments. MaxCyte has placed its cutting-edge instruments worldwide, with all of the top ten global biopharmaceutical companies, and has 70+partnered program licenses in cell therapy including 35+licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its biopharmaceutical industry partners to unlock the full potential of their products. Learn more atwww.maxcyte.com.